{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:57:33Z","timestamp":1789855053806,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Berufsgenossenschaftliches Klinikum Bergmannsheil gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myxofibrosarcoma (MFS) is characterized by infiltrative growth and high local recurrence (LR) rates. Despite consensus on the importance of negative resection margins (R0), the prognostic significance of quantitative margin width beyond R0 status remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 94 patients with histologically confirmed myxofibrosarcoma treated between 2000 and 2023. Resection margins, recurrence patterns, and treatment variables were analyzed using descriptive stratification, exploratory threshold scanning with multiplicity correction, and complementary computational approaches for internal signal exploration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Local recurrence occurred in 28\/84 patients (33%; 28\/79, 35% among those with documented recurrence status). Numeric margin width was available in 38\/84 cases (45%). Exploratory threshold analyses showed the smallest unadjusted signal near 0.3\u00a0mm, but this finding did not remain consistently significant after multiplicity correction. Radiotherapy was associated with numerically lower recurrence rates, although subgroup comparisons remained non-significant and vulnerable to confounding by indication. Complementary computational analyses yielded overlapping margin-related signals, but all such findings were interpreted as exploratory given the limited sample size, sparse events, and lack of external validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory analysis, very close resection margins may define a higher-risk zone for local recurrence, but the observed signal near 0.3\u00a0mm should not be interpreted as a clinically established threshold. R0 status (\u201ctumor not on ink\u201d) and anatomical barrier quality remain the primary determinants of margin adequacy in myxofibrosarcoma. Prospective multicenter validation with standardized pathology and harmonized time-to-event data is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04403-6","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:26:43Z","timestamp":1778491603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["How much is enough? Defining the critical resection margin in myxofibrosarcoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Christoph","family":"Wallner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Drysch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reinkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sogorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Dadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lehnhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Puscz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4403_CR1","doi-asserted-by":"publisher","first-page":"175883592210939","DOI":"10.1177\/17588359221093973","volume":"14","author":"S Vanni","year":"2022","unstructured":"Vanni S, De Vita A, Gurrieri L, Fausti V, Miserocchi G, Spadazzi C, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022;14:17588359221093973.","journal-title":"Ther Adv Med Oncol"},{"key":"4403_CR2","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/modpathol.2017.94","volume":"30","author":"E Heitzer","year":"2017","unstructured":"Heitzer E, Sunitsch S, Gilg MM, Lohberger B, Rinner B, Kashofer K, et al. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Mod Pathol. 2017;30:1698\u2013709.","journal-title":"Mod Pathol"},{"key":"4403_CR3","doi-asserted-by":"publisher","first-page":"38670","DOI":"10.1038\/s41598-025-09597-5","volume":"15","author":"LS Peschek","year":"2025","unstructured":"Peschek LS, Funovics PT, Hobusch GM, Schmid MP, Scharrer A, Brodowicz T, et al. Impact of resection margins on local recurrence in patients with myxofibrosarcoma. Sci Rep. 2025;15:38670.","journal-title":"Sci Rep"},{"key":"4403_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/CORR.0000000000002709","volume":"481","author":"A Yurtbay","year":"2023","unstructured":"Yurtbay A, Co\u015fkun HS, Say F, Dabak N. Is the Thickness of the Margin Associated With Local Recurrence and Survival in Patients With Myxofibrosarcoma? Clin Orthop Relat Res. 2023;481:2125\u201336.","journal-title":"Clin Orthop Relat Res"},{"key":"4403_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ans.18320","volume":"93","author":"I Rhee","year":"2023","unstructured":"Rhee I, Spazzoli B, Stevens J, Hansa A, Spelman T, Pang G, et al. Oncologic outcomes in myxofibrosarcomas: the role of a multidisciplinary approach and surgical resection margins. ANZ J Surg. 2023;93:577\u201384.","journal-title":"ANZ J Surg"},{"key":"4403_CR6","doi-asserted-by":"publisher","first-page":"12232","DOI":"10.1038\/s41598-024-63035-6","volume":"14","author":"T Tom\u00e1\u0161","year":"2024","unstructured":"Tom\u00e1\u0161 T, Apostolopoulos V, Pazourek L, Kub\u00ed\u010dek M, Staniczkov\u00e1 Zambo I, Ad\u00e1mkov\u00e1 D, et al. Clear surgical margins as a prognostic indicator for disease recurrence, with no impact on survival rates in patients with myxofibrosarcoma. Sci Rep. 2024;14:12232.","journal-title":"Sci Rep"},{"key":"4403_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ijrobp.2018.05.055","volume":"102","author":"R Boughzala-Bennadji","year":"2018","unstructured":"Boughzala-Bennadji R, Stoeckle E, Le P\u00e9choux C, M\u00e9eus P, Honor\u00e9 C, Attal J, et al. Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018;102:399\u2013406.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4403_CR8","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.3747\/co.20.1308","volume":"20","author":"R Kandel","year":"2013","unstructured":"Kandel R, Coakley N, Werier J, Engel J, Ghert M, Verma S, et al. Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline. Curr Oncol. 2013;20:e247\u201354.","journal-title":"Curr Oncol"},{"key":"4403_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02674-y","volume":"132","author":"AJ Hayes","year":"2025","unstructured":"Hayes AJ, Nixon IF, Strauss DC, Seddon BM, Desai A, Benson C, et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer. 2025;132:11\u201331.","journal-title":"Br J Cancer"},{"key":"4403_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.6004\/jnccn.2020.0058","volume":"18","author":"M von Mehren","year":"2020","unstructured":"von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, et al. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020;18:1604\u201312.","journal-title":"J Natl Compr Canc Netw"},{"key":"4403_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21037\/tcr-20-2588","volume":"10","author":"S Cao","year":"2021","unstructured":"Cao S, Li J, Zhang J, Li H. Development and validation of a prognostic nomogram for predicting the overall survival of myxofibrosarcoma patients: a large population-based study. Transl Cancer Res. 2021;10:923\u201337.","journal-title":"Transl Cancer Res"},{"key":"4403_CR12","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1093\/oncolo\/oyad332","volume":"29","author":"A Pogkas","year":"2024","unstructured":"Pogkas A, Reichardt P, Tunn P-U, Niethard M, Werner M, Ghani S. Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution. Oncologist. 2024;29:e544\u201352.","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"4403_CR13","doi-asserted-by":"publisher","first-page":"v198","DOI":"10.1093\/annonc\/mdq209","volume":"21","author":"PG Casali","year":"2010","unstructured":"Casali PG, Blay J-Y, ESMO\/CONTICANET\/EUROBONET. Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v198\u2013203.","journal-title":"Ann Oncol"},{"key":"4403_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/ajcp\/111.5.594","volume":"111","author":"Recommendations for reporting","year":"1999","unstructured":"Recommendations for reporting. soft tissue sarcomas. Am J Clin Pathol. 1999;111:594\u20138.","journal-title":"Am J Clin Pathol"},{"key":"4403_CR15","doi-asserted-by":"publisher","unstructured":"Wittenberg S, Paraskevaidis M, Jarosch A, Fl\u00f6rcken A, Brandes F, Striefler J et al. Surgical Margins in Soft Tissue Sarcoma Management and Corresponding Local and Systemic Recurrence Rates: A Retrospective Study Covering 11 Years and 169 Patients in a Single Institution. Life (Basel). 2022;12. Available from: https:\/\/doi.org\/10.3390\/life12111694.","DOI":"10.3390\/life12111694"},{"key":"4403_CR16","doi-asserted-by":"publisher","unstructured":"Sambri A, Caldari E, Fiore M, Zucchini R, Giannini C, Pirini MG et al. Margin Assessment in Soft Tissue Sarcomas: Review of the Literature. Cancers (Basel). 2021;13. Available from: https:\/\/doi.org\/10.3390\/cancers13071687.","DOI":"10.3390\/cancers13071687"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04403-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04403-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04403-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:46:44Z","timestamp":1778492804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04403-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4403"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04403-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, single-center cohort study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee of the Ruhr-University Bochum (approval number 20\u20137126).Written informed consent to participate and for the collection and analysis of clinical data was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}